Figure 1: Dosage compensation versus X-chromosome inactivation in animal species. Although dosage compensation is universal, X-chromosome inactivation has only been shown to take place in mammals with ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced the publication of a study in Transfusion Medicine 1 on the inactivation of the MERS (Middle Eastern Respiratory ...
Firm is pushing on with U.S. commercialization of CE-marked Intercept plasma and platelet system. Cerus hopes to raise about $21 million through a public offering of common stock and warrants, priced ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative agent for COVID-19, ...
Three coronaviruses (CoVs) have caused global outbreaks within the past 20 years, and with the COVID19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still ongoing, ...
One of the biggest concerns about blood transfusions is what might lurk in the blood – viruses, bacteria, parasites or even potentially dangerous white blood cells. Intercept, a pathogen inactivation ...
Biologics derived from mammalian sources are expected to undergo two orthogonal virus removal processes. One common processing step is a batch low-pH hold to inactivate enveloped viruses. Attempts to ...
Low pH inactivation is commonly used in monoclonal antibody purification processes to inactivate large enveloped viruses. Adjusting the pH to achieve this as part of a single-use biomanufacturing ...
(RTTNews) - Cerus Corp. (CERS) announced successful inactivation of SARS-CoV-2 with the INTERCEPT Blood System for Plasma. The data are consistent with prior INTERCEPT studies showing complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback